Purple Biotech AI Stock Analysis
Want to see PPBT full AI Analyst Report?
Purple Biotech (PPBT) AI Stock Analysis
Purple Biotech
(NASDAQ:PPBT)
The score is primarily weighed down by weak financial performance (minimal revenue, large losses, and ongoing cash burn despite low debt). Technicals provide some support via improving short-term momentum and price strength versus shorter moving averages, but valuation remains unfavorable due to negative earnings and no dividend yield data.
Purple Biotech (PPBT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $225.08K
- Dividend Yield
- ―
- Average Volume (3M)
- 1.26M
- Price to Earnings (P/E)
- -0.7
- Beta (1Y)
- 0.82
- Revenue Growth
- ―
- EPS Growth
- -151.47%
- Country
- US
- Employees
- 10
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Purple Biotech Business Overview & Revenue Model
Company Description
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline fea...
Purple Biotech Financial Statement Overview
Summary
Financial performance is weak: revenue is effectively nonexistent across recent periods, losses remain sizable (TTM net income about -24.6M), and cash flow is consistently negative (TTM operating/free cash flow about -7.76M). The main offset is low leverage with minimal debt (~0.13M TTM), but equity has declined sharply over time, reflecting ongoing burn and capital erosion.
Income Statement
9Very NegativeBalance Sheet
58NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -24.28M | -26.25M | -7.05M | -19.72M | -21.49M | -17.52M |
| Net Income | -24.49M | -26.39M | -7.24M | -19.88M | -21.67M | -18.38M |
Balance Sheet | ||||||
| Total Assets | 14.17M | 17.57M | 37.04M | 44.30M | 54.62M | 70.20M |
| Cash, Cash Equivalents and Short-Term Investments | 6.11M | 9.57M | 8.52M | 15.41M | 32.11M | 47.20M |
| Total Debt | 134.00K | 244.00K | 183.00K | 351.00K | 515.00K | 749.00K |
| Total Liabilities | 1.95M | 7.91M | 4.13M | 10.01M | 7.52M | 5.09M |
| Stockholders Equity | 12.27M | 9.71M | 32.86M | 34.21M | 46.91M | 64.83M |
Cash Flow | ||||||
| Free Cash Flow | -7.76M | -5.54M | -14.37M | -19.93M | -16.96M | -15.37M |
| Operating Cash Flow | -7.76M | -5.54M | -14.37M | -19.93M | -16.73M | -15.25M |
| Investing Cash Flow | 314.00K | 449.54K | 509.00K | 13.88M | 19.91M | 13.41M |
| Financing Cash Flow | 7.92M | 6.41M | 6.77M | 5.45M | 1.11M | 1.51M |
Purple Biotech Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PPBT, the sentiment is Positive. The current price of 1.63 is above the 20-day moving average (MA) of 1.21, above the 50-day MA of 1.39, and below the 200-day MA of 2.77, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 69.93 is Neutral, neither overbought nor oversold. The STOCH value of 99.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PPBT.
Purple Biotech Risk Analysis
Purple Biotech disclosed 77 risk factors in its most recent earnings report. Purple Biotech reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksPurple Biotech Peers Comparison
Overall Rating
PPBT49Neutral
TCRT45Neutral
KALA28Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $10.08M | -0.73 | -151.94% | ― | ― | -151.47% | |
| 45Neutral | $6.73M | -0.83 | -232.60% | ― | -50.00% | 20.95% | |
| 28Underperform | $2.68M | -0.00 | -222.32% | ― | ― | 78.25% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PPBT | Purple Biotech Ltd. | 1.63 | -5.57 | -77.37% | |
| TCRT | Alaunos Therapeutics Inc | 1.63 | -1.59 | -49.38% | |
| OGEN | Oragenics Inc | 0.20 | -0.91 | -81.89% | |
| PMCB | Pharmacyte Biotech, Inc. | 6.68 | -7.10 | -51.51% | |
| KALA | Kala Bio, Inc. | 0.14 | -34.81 | -99.61% |
Purple Biotech Corporate Events
Purple Biotech Reinstates Isaac Israel as Interim CEO in Leadership Reshuffle
Purple Biotech announced that its board appointed director and former chief executive Isaac Israel as interim CEO, effective October 5, 2026, as it searches for a permanent chief executive. Israel previously led the company from 2012 to 2022, briefly...
Purple Biotech Shareholders Approve All AGM Proposals, File Results with U.S. SEC
Purple Biotech reported that shareholders approved all proposals presented at its Annual General Meeting held on September 8, 2026, at the company’s offices in Rehovot. The resolutions, passed in accordance with Israeli Companies Law and the firm’s a...
Purple Biotech Gains New U.S. Patent Allowance for CAPTN-3 Cancer Immunotherapy Platform
On September 2, 2026, Purple Biotech reported that the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent application covering precursor tri-specific antibody constructs and methods of use. The allowance expands protection for...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 12, 2026
